Covered recipient · General Payments record
MAXWELL G ALSBACH
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2022–2024
$1,144.69
- Reported across 55 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $734.07 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $299.54 | 17 |
| GENZYME CORPORATION | $142.24 | 2 |
| Lundbeck LLC | $95.06 | 4 |
| Merz Pharmaceuticals, LLC | $90.33 | 5 |
| Teva Pharmaceuticals USA, Inc. | $50.03 | 3 |
| Lilly USA, LLC | $38.70 | 2 |
| Bioventus LLC | $18.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.36 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431860 | CMS |
| ABBVIE INC. | $11.97 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431862 | CMS |
| ABBVIE INC. | $23.87 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431864 | CMS |
| ABBVIE INC. | $19.33 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431866 | CMS |
| ABBVIE INC. | $24.00 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431868 | CMS |
| ABBVIE INC. | $25.85 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431870 | CMS |
| ABBVIE INC. | $19.01 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431872 | CMS |
| ABBVIE INC. | $5.63 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431874 | CMS |
| ABBVIE INC. | $11.99 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431876 | CMS |
| ABBVIE INC. | $19.22 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431878 | CMS |
| ABBVIE INC. | $6.79 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431880 | CMS |
| ABBVIE INC. | $25.37 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431882 | CMS |
| ABBVIE INC. | $15.46 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431884 | CMS |
| ABBVIE INC. | $24.10 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431886 | CMS |
| ABBVIE INC. | $15.51 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431888 | CMS |
| ABBVIE INC. | $10.18 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431890 | CMS |
| ABBVIE INC. | $23.90 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106431892 | CMS |
| Bioventus LLC | $18.17 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137452418 | CMS |
| GENZYME CORPORATION | $30.41 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139988081 | CMS |
| GENZYME CORPORATION | $111.83 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139988115 | CMS |
| Lilly USA, LLC | $17.57 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135841426 | CMS |
| Lilly USA, LLC | $21.13 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135841430 | CMS |
| Lundbeck LLC | $27.24 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145987566 | CMS |
| Lundbeck LLC | $32.44 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145987568 | CMS |
| Lundbeck LLC | $17.23 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145987570 | CMS |
| Lundbeck LLC | $18.15 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145987572 | CMS |
| Merz Pharmaceuticals, LLC | $18.10 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137959018 | CMS |
| Merz Pharmaceuticals, LLC | $17.50 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137959020 | CMS |
| Merz Pharmaceuticals, LLC | $24.80 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137959022 | CMS |
| Merz Pharmaceuticals, LLC | $14.63 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137959024 | CMS |
| Merz Pharmaceuticals, LLC | $15.30 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137959026 | CMS |
| Teva Pharmaceuticals USA, Inc. | $13.63 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151537823 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.45 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151537889 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.95 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151537949 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.